logo
Plus   Neg
Share
Email

Foamix Pharmaceuticals Ltd. (FOMX) Is Surging On Study Results

Foamix Pharmaceuticals Ltd. (FOMX) announced after the bell Tuesday that its Phase 3 clinical trial of FMX101 for the treatment of moderate-to-severe acne met both co-primary endpoints.

Foamix Pharmaceuticals has gapped open sharply higher Wednesday morning and is now up 1.29 at $7.21 on above average volume. The stock is challenging the highs of the year, trading at over a 7-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

$5 and under

0 Articles
Follow RTT